Early Detection of Prostate Cancer Using Novel ELISA-Based Biomarkers: Insights into Inflammatory and Tumor-Specific Pathways

The observed elevations of PSMA, IL-8, TGF-β, MIC-1/GDF15, YKL-40, and NGF in prostate cancer patients emphasize their value as diagnostic and prognostic indicators. These biomarkers reflect activation of inflammatory and tumor-specific pathways, supporting their clinical application in early detection and disease progression monitoring.